Business Wire

Transboundary Pollution Poses Growing Global Health Threat

Del

Disease-causing toxic pollution is a leading cause of death globally, and harms the health of millions of people, including those who live far from the source of the pollution, according to a new report issued today by the non-profit organization Pure Earth.

The findings of Pollution Knows No Borders, the first comprehensive report to aggregate expert analysis and relevant scientific literature on this topic, will be presented at a briefing in New York on Jan. 8 by Richard Fuller, President, Pure Earth; Gina McCarthy, Former US EPA Administrator, and current director, Center for Climate Health and the Global Environment, Harvard University; Janez Potočnik, Co-Chair of UN Intl. Resource Panel; Baskut Tuncak, UN Special Rapporteur, and others. (Interviews are available, click here to learn how to attend the briefing remotely.)

“When it comes to pollution, we are all connected. There is an invisible toxic thread that links workers being poisoned in poorer countries producing products, and consumers exposed to poisons while consuming these products. Reducing pollution is the right thing to do for children growing up in these countries, and it will also safeguard the health of children in wealthier consumer nations,” says Richard Fuller, President, Pure Earth.

The report documents the global harm caused by the movement of toxins from low- and middle-income countries that lack substantive pollution controls. Examples include:

  • Air pollution – Toxic particles from burning coal in Eastern Europe affect Western Europe. Particles from China form a significant part of air pollution in California.
  • Water pollution – Mercury from Asia and Africa ends up in the fish we eat in the US and Europe. Contaminated industrial wastewater in India and China is used to water crops, and affects spices and grains imported into the West.
  • Food and Products. Toxins, especially heavy metals, are regularly found in imported products, including sweets and candies, makeup, school supplies and more. Food for toddlers and babies often test above regulatory standards for lead, cadmium and arsenic.

Children are most at risk. There has been a rapid increase in noncommunicable diseases among children in recent decades, including diabetes, birth defects, autism spectrum disorder, leukemia, and more, a development that medical experts are calling a “silent epidemic.” Most of those diseases are expected to be the result of environmental exposures.

The solution is to prevent pollution at its source by using cleaner fuels, installing wastewater treatment plants for effluents, using safe production techniques and upgrading toxic informal work practices. These solutions are usually cost effective and often have the added benefit of stemming climate change and improving local economies.

Download the full report at  https://www.pureearth.org/pollution-knows-no-borders/ .

Read the full press release, access infographics and interactive data visualizations  here .

Demand action by signing a petition urging world leaders to prioritize pollution control at the source, protect children’s health, and increase funding for pollution cleanup.

Interviews are available upon request with speakers and authors.

About Pure Earth

Pure Earth is an international non-profit organization dedicated to solving pollution problems in low and middle-income countries, where human health is at risk. www.pureearth.org

Contact information

Angela Bernhardt, Pure Earth angela@pureearth.org
Mag Sim, Pure Earth mag@pureearth.org
Tel: +1 212 870 3490

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Fishawack continues to build best-in-class service offering with Dudnyk acquisition20.3.2019 13:00:00 CETPressemelding

Fishawack, a leading independent healthcare communications specialist, is excited to announce its acquisition of Dudnyk, the Philadelphia-based healthcare communications agency. Dudnyk is an award-winning, full-service agency that specializes in creating insight-driven, authentic brand experiences that unite specialty physicians and their patients. They leverage strategic, scientific, and creative capabilities to serve clients in the biotech, pharmaceutical, and medical device industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190320005204/en/ Dudnyk leadership team includes Christopher Tobias, PhD, President; Laurie Bartolomeo, EVP, Creative Director; Drew Desjardins, EVP, Chief Strategy Officer; Annemarie Armstrong, EVP, Director of Client Services; John Kemble, EVP, Creative Producer. (Photo: Business Wire) Fishawack’s goal is to increase the range of healthcare communications services that it can offer to commerc

ExaGrid Nominated in Six Categories for the 2019 Network Computing Awards20.3.2019 12:00:00 CETPressemelding

ExaGrid ®, a leading provider of intelligent hyperconverged storage for backup, today announced that it has been nominated in six categories for the 2019 Network Computing Awards. ExaGrid has become a finalist for Data Centre Product of the Year, The Return on Investment Award, Hardware Product of the Year, Product of the Year, The Customer Service Award, and Company of the Year. Voting to determine the winner in each category is underway now and closes on April 23. The results will be revealed at an evening award ceremony in London on May 2. ExaGrid’s model EX63000E backup storage appliance with data deduplication is a nominee in four categories. The model provides the largest scale-out system and offers up to a 2PB full backup with an ingest rate of 432TB/hr, which is three times faster than any other backup storage on the market. “We are thrilled to be nominated by IT staff, and recognized by Network Computing, in six prestigious categories this year,” said Bill Andrews, CEO and Pre

Eos Biosciences Issued Patent for New Approach to Shuttle Therapeutics Across the Blood-Brain Barrier to Treat Brain Diseases20.3.2019 11:30:00 CETPressemelding

Eos Biosciences, Inc. (Eos), a nanomedicines company developing an efficient and versatile nanobiologic particle-based platform technology (Eosomes), announced that the U.S. Patent and Trademark Office has granted Eos Biosciences Patent No. 10,183,078, relating to a novel approach of using HER3-targeted Eosomes as a shuttle system for transporting various classes of therapeutics across the blood-brain barrier for treatment of brain disorders, including brain cancer. The patent is owned by Cedars-Sinai Medical Center and is exclusively licensed to Eos Biosciences. Details of the system will be highlighted in an upcoming manuscript from Lali Medina-Kauwe, PhD, Professor, Department of Biomedical Sciences, Cedars-Sinai. Omar Haffar, Ph.D., Founder, President and Chief Executive Officer, commented, “We’re very excited by the issuance of this pivotal patent and look forward to receiving similar approvals in other countries. This patent adds to Eos’ considerable IP portfolio covering the Eos

Pfizer Secures Exclusive Option to Acquire Gene Therapy Company Vivet Therapeutics20.3.2019 10:45:00 CETPressemelding

Vivet Therapeutics (“Vivet”), a privately held gene therapy biotech company dedicated to developing gene therapy treatments for inherited liver disorders with high unmet medical need, and Pfizer Inc. (NYSE: PFE) announced today that Pfizer has acquired a 15% equity interest in Vivet and secured an exclusive option to acquire all outstanding shares. Pfizer and Vivet will collaborate on the development of VTX-801, Vivet’s proprietary treatment for Wilson disease. Wilson disease is a devastating, rare, chronic, and potentially life-threatening liver disorder of impaired copper transport that causes serious copper poisoning. In patients with Wilson disease, a monogenetic mutation disables the normal copper biliary excretion pathway leading to excess copper accumulation in the liver and other organs including the central nervous system. Untreated, Wilson disease results in various combinations and severity of hepatic (fibrosis and cirrhosis), neurologic and psychiatric symptoms, which can b

Fintech Company Rimilia Appoints Kevin Kimber as CEO20.3.2019 10:00:00 CETPressemelding

Rimilia, a fintech company helping finance departments simplify the complex, has appointed Kevin Kimber as CEO. The news follows another strong year for Rimilia. In 2018, Rimilia opened offices in Central London and Denver, Colorado in the U.S., and reported significant revenue growth on the previous year. Rimilia was founded in 2008 and its platform, created by finance professionals, uses RPA (robotic process automation) technology to help finance teams fast-track their cash flow by providing clearer information and better control. It has quickly become the industry leader, trusted by a number of global brands from HSBC to DHL and Santander, to provide visibility, improve efficiencies and guarantee cash flow. Rimilia works with any currency, any bank and in any language, and on average delivers 70% cost-savings and an 80% reduction in manual effort to its customers. Kevin joins Rimilia from Eight Roads Ventures (one of Rimilia’s investors), where he was a Venture Partner, advising its

Knopp Biosciences Enters Collaboration with Leading UK Investigators to Commence Phase 2 Clinical Trial of Dexpramipexole in Severe Eosinophilic Asthma20.3.2019 10:00:00 CETPressemelding

Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases with high unmet need, today announced a collaboration with a consortium of leading medical researchers in the United Kingdom to evaluate the ability of Knopp’s lead drug candidate, dexpramipexole, to reduce exacerbations in people with severe eosinophilic asthma. The project is chiefly funded by the National Institute for Health Research (NIHR) and Medical Research Council (MRC) of the UK. The Chief Investigator for the Phase 2 multi-center, 52-week trial is Professor Salman Siddiqui, Professor of Airway Diseases at the University of Leicester and Consultant Respiratory Physician at Leicester’s Hospitals. Dexpramipexole is an orally available small molecule shown to selectively reduce eosinophil levels in multiple clinical trials, including in a Phase 2 study in hypereosinophilic syndrome (HES) and a Phase 2 trial in chr